| 1.92 0.22 (12.94%) | 04-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.66 | 1-year : | 3.15 |
| Resists | First : | 2.28 | Second : | 2.7 |
| Pivot price | 1.91  |
|||
| Supports | First : | 1.6 | Second : | 1.33 |
| MAs | MA(5) : | 1.82 | MA(20) : | 1.96 |
| MA(100) : | 1.51 |
MA(250) : | 1.13 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 34.7 |
D(3) : | 32.8 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 2.7 | Low : | 0.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EQ ] has closed below upper band by 49.5%. Bollinger Bands are 23.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.93 - 1.94 | 1.94 - 1.95 |
| Low: | 1.69 - 1.71 | 1.71 - 1.72 |
| Close: | 1.9 - 1.92 | 1.92 - 1.94 |
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Mon, 13 Apr 2026
Equillium (EQ) price target increased by 27.27% to 7.14 - MSN
Tue, 07 Apr 2026
Equillium (NASDAQ: EQ) registers 18.9M resale shares from RA Capital - Stock Titan
Tue, 07 Apr 2026
Equillium (EQ) Gains Overweight Rating with Promising Future Prospects - GuruFocus
Thu, 02 Apr 2026
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Mon, 30 Mar 2026
Reverse split range 1-for-2–1-for-20; Equillium (NASDAQ: EQ) seeks 400M cap - Stock Titan
Thu, 26 Mar 2026
[EFFECT] Equillium, Inc. SEC Filing - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 63 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 20.1 (%) |
| Held by Institutions | 60.8 (%) |
| Shares Short | 2,000 (K) |
| Shares Short P.Month | 1,970 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -51.4 % |
| Return on Equity (ttm) | -94 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.38 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -23 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -4.93 |
| PEG Ratio | 0 |
| Price to Book value | 4.08 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|